689
Participants
Start Date
March 23, 2023
Primary Completion Date
August 28, 2028
Study Completion Date
August 28, 2028
C. difficile vaccine (previously studied formulation).
Toxoid based Clostridioides difficile vaccine (previously studied formulation) given as an intramuscular injection
C. difficile vaccine formulation 1.
C. difficile vaccine formulation 1 given as an intramuscular injection
C. difficile vaccine formulation 2.
C. difficile vaccine formulation 2 given as an intramuscular injection
C. difficile vaccine formulation 3.
C. difficile vaccine formulation 3 given as an intramuscular injection
Saline Placebo.
0.9% sodium chloride solution given as an intramuscular injection
NYU Langone Health, New York
Rochester Clinical Research, LLC, Rochester
Indago Research & Health Center, Inc, Hialeah
Charisma Medical and Research Center, Miami Lakes
Research Centers of America ( Hollywood ), Hollywood
Research Centers of America, Hollywood
Private Practice - Dr. Hector Fabregas, Pembroke Pines
DBC Research USA, Pembroke Pines
Alliance for Multispecialty Research, LLC, Coral Gables
Miami Clinical Research, Miami
New Horizon Research Center, Miami
BRCR Medical Center Inc., Plantation
Clinical Research Trials of Florida, Tampa
CTI Clinical Research Center, Cincinnati
Prism Research LLC dba Nucleus Network, Saint Paul
Great Lakes Clinical Trials - Gurnee, Gurnee
Great Lakes Clinical Trials - Ravenswood, Chicago
Washington University School of Medicine, St Louis
Alliance for Multispecialty Research, LLC, Wichita
DM Clinical Research - MDC, Tomball
Benchmark Research, Austin
Hope Research Institute, Phoenix
The Pain Center of Arizona, Phoenix
HOPE Research Institute, Phoenix
Anaheim Clinical Trials, LLC, Anaheim
Lead Sponsor
Pfizer
INDUSTRY